These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 34569453)

  • 21. Reduction in Neisseria meningitidis infection in Italy after Meningococcal C conjugate vaccine introduction: A time trend analysis of 1994-2012 series.
    de Waure C; Miglietta A; Nedovic D; Mereu G; Ricciardi W
    Hum Vaccin Immunother; 2016; 12(2):467-73. PubMed ID: 26308192
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Introduction of a second MenB vaccine into Europe - needs and opportunities for public health.
    Findlow J; Nuttens C; Kriz P
    Expert Rev Vaccines; 2019 Mar; 18(3):225-239. PubMed ID: 30821535
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity and safety of MenACWY-TT, a quadrivalent meningococcal tetanus toxoid conjugate vaccine recently licensed in the United States for individuals ≥2 years of age.
    Marshall GS; Pelton SI; Robertson CA; Oster P
    Hum Vaccin Immunother; 2022 Nov; 18(6):2099142. PubMed ID: 35947774
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk of invasive meningococcal disease in university students in England and optimal strategies for protection using MenACWY vaccine.
    Mandal S; Campbell H; Ribeiro S; Gray S; Carr T; White J; Ladhani SN; Ramsay ME
    Vaccine; 2017 Oct; 35(43):5814-5818. PubMed ID: 28928076
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Can we control all-cause meningococcal disease in Europe?
    Sadarangani M; Pollard AJ
    Clin Microbiol Infect; 2016 Dec; 22 Suppl 5():S103-S112. PubMed ID: 27129415
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of meningococcal polysaccharide serogroups A, C, W-135 and Y conjugate vaccine in Australian adolescents.
    Si S; Zomer E; Fletcher S; Lee J; Liew D
    Vaccine; 2019 Aug; 37(35):5009-5015. PubMed ID: 31301916
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 'Be on the TEAM' Study (Teenagers Against Meningitis): protocol for a controlled clinical trial evaluating the impact of 4CMenB or MenB-fHbp vaccination on the pharyngeal carriage of meningococci in adolescents.
    Carr J; Plested E; Aley P; Camara S; Davis K; MacLennan JM; Gray S; Faust SN; Borrow R; Christensen H; Trotter C; Maiden MCJ; Finn A; Snape MD;
    BMJ Open; 2020 Oct; 10(10):e037358. PubMed ID: 33093030
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disparities in healthcare providers' interpretations and implementations of ACIP's meningococcal vaccine recommendations.
    Huang L; Goren A; Lee LK; Li VW; Dempsey A; Srivastava A
    Hum Vaccin Immunother; 2020 Apr; 16(4):933-944. PubMed ID: 31634035
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Invasive meningococcal disease epidemiology and vaccination strategies in four Southern European countries: a review of the available data.
    Zografaki I; Detsis M; Del Amo M; Iantomasi R; Maia A; Montuori EA; Mendez C
    Expert Rev Vaccines; 2023; 22(1):545-562. PubMed ID: 37316234
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Cohn AC; MacNeil JR; Clark TA; Ortega-Sanchez IR; Briere EZ; Meissner HC; Baker CJ; Messonnier NE;
    MMWR Recomm Rep; 2013 Mar; 62(RR-2):1-28. PubMed ID: 23515099
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Public health perspective of a pentavalent meningococcal vaccine combining antigens of MenACWY-CRM and 4CMenB.
    Bekkat-Berkani R; Fragapane E; Preiss S; Rappuoli R; Sohn WY; Soumahoro L; Vadivelu K
    J Infect; 2022 Nov; 85(5):481-491. PubMed ID: 36087745
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of the Pfizer Pentavalent Meningococcal Vaccine Among Persons Aged ≥10 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023.
    Collins JP; Crowe SJ; Ortega-Sanchez IR; Bahta L; Campos-Outcalt D; Loehr J; Morgan RL; Poehling KA; McNamara LA
    MMWR Morb Mortal Wkly Rep; 2024 Apr; 73(15):345-350. PubMed ID: 38635488
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Invasive meningococcal disease epidemiology and control measures: a framework for evaluation.
    Caro JJ; Möller J; Getsios D; Coudeville L; El-Hadi W; Chevat C; Nguyen VH; Caro I
    BMC Public Health; 2007 Jun; 7():130. PubMed ID: 17603880
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incidence of Meningococcal Disease Before and After Implementation of Quadrivalent Meningococcal Conjugate Vaccine in the United States.
    Mbaeyi S; Pondo T; Blain A; Yankey D; Potts C; Cohn A; Hariri S; Shang N; MacNeil JR
    JAMA Pediatr; 2020 Sep; 174(9):843-851. PubMed ID: 32687590
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MenACWY-TT vaccine for active immunization against invasive meningococcal disease.
    Papaevangelou V; Spyridis N
    Expert Rev Vaccines; 2012 May; 11(5):523-37. PubMed ID: 22827239
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Concomitant administration of a fully liquid ready-to-use DTaP-IPV-HB-PRP-T hexavalent vaccine with a meningococcal ACWY conjugate vaccine in toddlers.
    Vesikari T; Borrow R; Da Costa X; Thomas S; Eymin C; Boisnard F; Lockhart S
    Vaccine; 2018 Dec; 36(52):8019-8027. PubMed ID: 30471953
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-world implementation of 4-component meningococcal serogroup B vaccine (4CMenB): implications for clinical practices.
    Sohn WY; Tahrat H; Novy P; Bekkat-Berkani R
    Expert Rev Vaccines; 2022 Mar; 21(3):325-335. PubMed ID: 35068299
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An update of clinical experience with the quadrivalent meningococcal ACWY-CRM conjugate vaccine.
    Keshavan P; Pellegrini M; Vadivelu-Pechai K; Nissen M
    Expert Rev Vaccines; 2018 Oct; 17(10):865-880. PubMed ID: 30198805
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Meningococcal disease epidemiology in Brazil (2005-2018) and impact of MenC vaccination.
    Aparecido Nunes A; De Jesus Lopes De Abreu A; Cintra O; A C T Cintra M; Barbosa Coelho E; Nogueira Castro De Barros E
    Vaccine; 2021 Jan; 39(3):605-616. PubMed ID: 33358262
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Meningococcal serogroup A, C, W₁₃₅ and Y conjugated vaccine: a cost-effectiveness analysis in the Netherlands.
    Hepkema H; Pouwels KB; van der Ende A; Westra TA; Postma MJ
    PLoS One; 2013; 8(5):e65036. PubMed ID: 23741448
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.